{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:52:23Z","timestamp":1774925543566,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"World Health Organisation"},{"name":"Advisory Council on the Misuse of Drugs, European Monitoring Centre for Drugs and Drug Addiction"},{"name":"United Nations Office on Drugs and Crime"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,27]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Recent work in the UK estimated the prevalence of current cannabinoid-based vaping to be higher than in the USA, a factor previously associated with e-cigarette or vaping-associated lung injury (EVALI). Research in the USA has demonstrated that attendances to emergency departments relating to e-cigarettes began to rise before the EVALI outbreak, suggesting that vapers also experience milder forms of vaping-related illness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>Quantify symptom prevalence and healthcare utilization amongst current UK vapers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Voluntary online survey of individuals aged 16 and over within the UK.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Anonymized data were collected on demographics, vaping\/smoking status and vaping substances used. Current vapers were asked about the presence of 10 prevalent symptoms from previous US EVALI case series, healthcare attendances and diagnoses given. Risk-ratios were calculated to compare the likelihood of symptoms and attendances between substances.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 2477 complete responses were analysed. In all, 397 respondents were current vapers. Symptom prevalence within the previous 12\u2009months ranged from 3.8% to 30.5% (bloody sputum, cough). Healthcare attendances per symptomatic respondent ranged from 0.1 to 1.4 (bloody sputum, shortness of breath). Current vapers of cannabinoid-based products (alone\/in combination) had the most attendances per symptomatic respondent for 9\/10 symptoms and were more likely to report symptoms aside from \u2018cough\u2019 (nicotine-free e-liquids [risk ratio = 1.7]). Clinicians reportedly never diagnosed vaping-related illness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>UK vapers experience symptoms previously reported in EVALI cases for which they also seek healthcare. Users of cannabinoid-based products were more likely to report symptoms and accounted for a higher healthcare burden. UK vapers may also experience vaping-related illness that does not meet EVALI case criteria.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/qjmed\/hcad210","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T20:39:32Z","timestamp":1695415172000},"page":"993-1001","source":"Crossref","is-referenced-by-count":2,"title":["The Emerging Cloud: a survey of vapers, their health and utilization of healthcare within the UK"],"prefix":"10.1093","volume":"116","author":[{"given":"L J","family":"Sund","sequence":"first","affiliation":[{"name":"St Thomas' Hospital , Department of Emergency Medicine, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s Health Partners , Westminster Bridge Rd, London SE1 7EH, UK"},{"name":"St Thomas' Hospital , Department of Clinical Toxicology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s Health Partners , Westminster Bridge Rd, London SE1 7EH, UK"},{"name":"St Thomas' Hospital campus , Faculty of Life Sciences and Medicine, King\u2019s College London , Westminster Bridge Rd, London SE1 7EH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P I","family":"Dargan","sequence":"additional","affiliation":[{"name":"St Thomas' Hospital , Department of Clinical Toxicology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s Health Partners , Westminster Bridge Rd, London SE1 7EH, UK"},{"name":"St Thomas' Hospital campus , Faculty of Life Sciences and Medicine, King\u2019s College London , Westminster Bridge Rd, London SE1 7EH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J R H","family":"Archer","sequence":"additional","affiliation":[{"name":"St Thomas' Hospital , Department of Clinical Toxicology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s Health Partners , Westminster Bridge Rd, London SE1 7EH, UK"},{"name":"St Thomas' Hospital campus , Faculty of Life Sciences and Medicine, King\u2019s College London , Westminster Bridge Rd, London SE1 7EH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M S","family":"Blundell","sequence":"additional","affiliation":[{"name":"St Thomas' Hospital , Department of Emergency Medicine, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s Health Partners , Westminster Bridge Rd, London SE1 7EH, UK"},{"name":"St Thomas' Hospital , Department of Clinical Toxicology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s Health Partners , Westminster Bridge Rd, London SE1 7EH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D M","family":"Wood","sequence":"additional","affiliation":[{"name":"St Thomas' Hospital , Department of Clinical Toxicology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s Health Partners , Westminster Bridge Rd, London SE1 7EH, UK"},{"name":"St Thomas' Hospital campus , Faculty of Life Sciences and Medicine, King\u2019s College London , Westminster Bridge Rd, London SE1 7EH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"2023122810031295000_hcad210-B1","volume-title":"Use of e-Cigarettes (Vapes) Among Adults in Great Britain","author":"Action on Smoking and Health (ASH)","year":"2022"},{"key":"2023122810031295000_hcad210-B2","volume-title":"Smoking in England: E-Cigarettes Latest Trends","author":"Buss","year":"2023"},{"key":"2023122810031295000_hcad210-B3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/qjmed\/hcac220","article-title":"The unseen cloud: a survey of vaping practices and the acquisition of vaping products within the UK","volume":"116","author":"Sund","year":"2023","journal-title":"QJM"},{"key":"2023122810031295000_hcad210-B4","volume-title":"Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"2023122810031295000_hcad210-B5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/15563650.2022.2160342","article-title":"E-cigarette or vaping-associated lung injury (EVALI): a review of international case reports from outside the United States of America","volume":"61","author":"Sund","year":"2023","journal-title":"Clin Toxicol (Phila)"},{"key":"2023122810031295000_hcad210-B6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41479-020-00075-2","article-title":"E-cigarette, or vaping, product use-associated lung injury: a review","volume":"12","author":"Belok","year":"2020","journal-title":"Pneumonia (Nathan)"},{"key":"2023122810031295000_hcad210-B7","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(19)32679-0","article-title":"Clinical presentation, treatment, and short-term outcomes of lung injury associated with ecigarettes or vaping: a prospective observational cohort study","volume":"394","author":"Blagev","year":"2019","journal-title":"Lancet"},{"key":"2023122810031295000_hcad210-B8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1056\/NEJMoa1911614","article-title":"Pulmonary illness related to e-cigarette use in Illinois and Wisconsin \u2013 final report","volume":"382","author":"Layden","year":"2020","journal-title":"N Engl J Med"},{"key":"2023122810031295000_hcad210-B9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S2213-2600(19)30415-1","article-title":"E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach","volume":"7","author":"Kalininskiy","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2023122810031295000_hcad210-B10","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMsr1915313","article-title":"Syndromic surveillance for e-cigarette, or vaping, product use-associated lung injury","volume":"382","author":"Hartnett","year":"2020","journal-title":"N Engl J Med"},{"key":"2023122810031295000_hcad210-B11","article-title":"Healthcare utilisation and expenditures attributable to current e-cigarette use among US adults","author":"Wang","year":"2022","journal-title":"Tob Control"},{"key":"2023122810031295000_hcad210-B12","volume-title":"Vaping in England: An Evidence Update February 2019.","author":"McNeill","year":"2019"},{"key":"2023122810031295000_hcad210-B13","volume-title":"Nicotine Vaping in England: An Evidence Update Including Health Risks and Perceptions","author":"McNeill","year":"2022"},{"key":"2023122810031295000_hcad210-B14","doi-asserted-by":"crossref","first-page":"107838","DOI":"10.1016\/j.pharmthera.2021.107838","article-title":"Toxicology of flavoring- and cannabis-containing e-liquids used in electronic delivery systems","volume":"224","author":"Stefaniak","year":"2021","journal-title":"Pharmacol Ther"},{"key":"2023122810031295000_hcad210-B15","volume-title":"Use of E-Cigarettes (vapes) among Young People in Great Britain","author":"Action on Smoking and Health (ASH)","year":"2022"},{"key":"2023122810031295000_hcad210-B16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tcm.2016.03.001","article-title":"Cardiovascular toxicity of nicotine: implications for electronic cigarette use","volume":"26","author":"Benowitz","year":"2016","journal-title":"Trends Cardiovasc Med"},{"issue":"Suppl 1","key":"2023122810031295000_hcad210-B17","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1136\/tobaccocontrol-2012-050860","article-title":"Reducing the nicotine content to make cigarettes less addictive","volume":"22","author":"Benowitz","year":"2013","journal-title":"Tob Control"},{"key":"2023122810031295000_hcad210-B18","first-page":"1","article-title":"Prospective study of e-cigarette use and respiratory symptoms in adolescents and young adults","volume":"0","author":"Tackett","year":"2023","journal-title":"Thorax"},{"key":"2023122810031295000_hcad210-B19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12931-016-0367-y","article-title":"Electronic cigarettes: a survey of perceived patient use and attitudes among members of the British thoracic oncology group","volume":"17","author":"Sherratt","year":"2016","journal-title":"Respir Res"},{"key":"2023122810031295000_hcad210-B20","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.3399\/bjgp18X699821","article-title":"GPs\u2019 and nurses\u2019 perceptions of electronic cigarettes in England: a qualitative interview study","volume":"69","author":"Stepney","year":"2019","journal-title":"Br J Gen Pract"},{"key":"2023122810031295000_hcad210-B21","volume-title":"E-cigarette Use or Vaping: Reporting Suspected Adverse Reactions, Including Lung Injury","author":"Medicine and Healthcare products Regulatory Agency","year":"2020"},{"key":"2023122810031295000_hcad210-B22","volume-title":"National Smoking Cessation Audit 2021: Management of Tobacco Dependency in Acute Care Trusts: Audit Report","author":"The British Thoracic Society","year":"2021"},{"key":"2023122810031295000_hcad210-B23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/psb.1917","article-title":"E-cigarettes: informing the conversation with patients","volume":"32","author":"Barton","year":"2021","journal-title":"Prescriber"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcad210\/51842021\/hcad210.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/116\/12\/993\/54913275\/hcad210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/116\/12\/993\/54913275\/hcad210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T10:58:00Z","timestamp":1703761080000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article\/116\/12\/993\/7280154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,9,21]]},"published-print":{"date-parts":[[2023,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcad210","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"value":"1460-2725","type":"print"},{"value":"1460-2393","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,9,21]]}}}